Salarius Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
David Arthur
Chief executive officer
US$544.6k
Total compensation
| CEO salary percentage | 91.8% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | no data |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Salarius pharmaceuticals announces 1-for-25 reverse stock split
Oct 14Salarius adds 12% after updates on clinical programs and financials
Sep 13Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers
Aug 22Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01
Aug 08Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
Aug 02Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Jun 07Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
May 27Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain
Feb 09
Salarius Pharmaceuticals receives second installment of $1.7M in payments
Jan 13Salarius Pharma raises $3.5M via warrant exercise
Dec 11Salarius Pharmaceuticals EPS in-line, beats on revenue
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$5m |
| Jun 30 2024 | n/a | n/a | -US$6m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$545k | US$500k | -US$13m |
| Sep 30 2023 | n/a | n/a | -US$18m |
| Jun 30 2023 | n/a | n/a | -US$30m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$941k | US$500k | -US$32m |
| Sep 30 2022 | n/a | n/a | -US$29m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$677k | US$379k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$1m | US$340k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$518k | US$315k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$3m |
| Dec 31 2018 | US$275k | US$258k | -US$2m |
Compensation vs Market: David's total compensation ($USD544.60K) is about average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Arthur (61 yo)
5.3yrs
Tenure
US$544,600
Compensation
Mr. David J. Arthur, M.B.A., has been President at Salarius Pharmaceuticals, Inc since July 19, 2019 and Chief Executive Officer & Director at Salarius Pharmaceuticals, Inc. since July 2019. Mr. Arthur ser...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.3yrs | US$544.60k | 0.43% $ 8.4k | |
| Independent Director | 4.4yrs | US$53.76k | 0.026% $ 504.3 | |
| Independent Director | 5.3yrs | US$45.26k | 0.012% $ 246.6 | |
| Independent Director | 5.3yrs | US$67.26k | 0.029% $ 564.5 | |
| Chairman of the Board | 5.3yrs | US$82.26k | 0.025% $ 489.1 | |
| Independent Director | 5.3yrs | US$64.76k | 0.024% $ 465.8 |
5.3yrs
Average Tenure
63yo
Average Age
Experienced Board: SLRX's board of directors are considered experienced (5.3 years average tenure).